Clinical Trial Update: IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating IRX-2 regimen with durvalumab for incurable head and neck squamous cell carcinoma has completed, including multiple head and neck cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma
• Paranasal Sinus Squamous Cell Carcinoma
• Squamous Cell Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• IRX-2

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Status: COMPLETED